



22 November 2017

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000
Attention: Isabelle Andrews
By email only: isabelle.andrews@asx.com.au

Dear Madam,

ASX PRICE QUERY

We refer to the price query issued by the Australian Securities Exchange on Tuesday, 21 November 2017 and comment as follows:

1. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.

However, the Company notes that it is a party to ongoing discussions in relation to ethics approvals for planned clinical trials and new collaborations, in line with its ongoing business practices, but no formal agreements have been entered into, and the Company does not reasonably expect that this would explain the trading in the Company's shares.

2. As referred to above, there is no announcement that the Company could currently make in relation to any ongoing discussions and the Company would not reasonably expect to announce anything unless and until any formal agreements were entered into.
3. The Company continues to execute its business plan and is in constant discussion and negotiation with parties relating to research and development opportunities and trials relating to its medical cannabis products. However, no new agreements have been entered into and the Company is not in a position to make any announcements in relation to anything that has not already been announced to the market.

The Company notes however that there has been strong support more broadly for the medical cannabis companies listed on ASX over recent times, and the sector continues to grow and develop. In addition, the Company has been made aware of a recent report recommending the Company as a 'strong buy', but the Company did not commission the report and has not provided any input into the report and has not seen the report.



4. The Company confirms that in its opinion it is, and has been at all times, in compliance with Listing Rule 3.1.
5. The Company confirms its responses above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of the Company with delegated authority from the board to respond to ASX on disclosure matters.

Yours sincerely



Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.



21 November 2017

Mr Tim Slate
Company Secretary
Zelda Therapeutics Limited
Level 6
105 St Georges Terrace
Perth WA 6000

By email: tim@catalystcorporate.com.au

Dear Mr Slate

Zelda Therapeutics Limited (“ZLD”) price query

We note the change in the price of ZLD’s securities from an intra-day low of \$0.09 to an intra-day high of \$0.117 today Tuesday, 21 November 2017.

We also note the significant increase in the volume of ZLD’s securities traded today Tuesday, 21 November 2017.

In light of this, ASX asks ZLD to respond separately to each of the following questions and requests for information:

1. Is ZLD aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is “yes”:
 - a) Is ZLD relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?

Please note that the recent trading in ZLD’s securities would suggest to ASX that such information may have ceased to be confidential and therefore ZLD may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation.
 - b) Can an announcement be made immediately?

Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).
 - c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is “no”, is there any other explanation that ZLD may have for the recent trading in its securities?
4. Please confirm that ZLD is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

5. Please confirm that ZLD's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of ZLD with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than **2:00 pm WST on Tuesday 21 November 2017**. If we do not have your response by then, ASX will have no choice but to consider suspending trading in ZLD's securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ZLD's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail at Isabelle.andrews@asx.com.au or to TradingHaltsPerth@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rules 3.1 and 3.1A

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

In responding to this letter, you should have regard to ZLD's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

It should be noted that ZLD's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in ZLD's securities under Listing Rule 17.1.

If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.



We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

If you have any queries or concerns about any of the above, please contact me immediately.

Yours sincerely

[Sent electronically without signature]

Isabelle Andrews

Adviser Listings Compliance (Perth)